XLO vs. CLLS, CRDF, FBRX, HURA, CHRS, BHST, IKT, ACOG, ZURA, and CABA
Should you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Cellectis (CLLS), Cardiff Oncology (CRDF), Forte Biosciences (FBRX), TuHURA Biosciences (HURA), Coherus Oncology (CHRS), BioHarvest Sciences (BHST), Inhibikase Therapeutics (IKT), Alpha Cognition (ACOG), Zura Bio (ZURA), and Cabaletta Bio (CABA). These companies are all part of the "pharmaceutical products" industry.
Xilio Therapeutics vs. Its Competitors
Xilio Therapeutics (NASDAQ:XLO) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.
In the previous week, Xilio Therapeutics had 1 more articles in the media than Cellectis. MarketBeat recorded 4 mentions for Xilio Therapeutics and 3 mentions for Cellectis. Cellectis' average media sentiment score of 1.61 beat Xilio Therapeutics' score of 0.48 indicating that Cellectis is being referred to more favorably in the news media.
Xilio Therapeutics presently has a consensus price target of $3.00, indicating a potential upside of 307.28%. Cellectis has a consensus price target of $4.00, indicating a potential upside of 38.41%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Xilio Therapeutics is more favorable than Cellectis.
54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 5.2% of Xilio Therapeutics shares are held by insiders. Comparatively, 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Cellectis has higher revenue and earnings than Xilio Therapeutics. Cellectis is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.
Xilio Therapeutics has a beta of -0.14, meaning that its share price is 114% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.03, meaning that its share price is 203% more volatile than the S&P 500.
Cellectis has a net margin of -100.69% compared to Xilio Therapeutics' net margin of -374.79%. Cellectis' return on equity of -68.05% beat Xilio Therapeutics' return on equity.
Summary
Cellectis beats Xilio Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Xilio Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xilio Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:XLO) was last updated on 9/12/2025 by MarketBeat.com Staff
